Genmab Drops 2 Antibody Assets, Including Another ProfoundBio ADC

Why It Matters

The cuts highlight Genmab’s commitment to pipeline discipline, preserving capital for high‑potential late‑stage drugs and sustaining investor confidence amid a competitive oncology market.

Key Takeaways

• Genmab dropped GEN1286 ADC after enrolling only 23 patients.
• Safety concerns also halted GEN1057 bispecific antibody from DuoBody platform.
• Rina‑S remains sole ProfoundBio asset, now in Phase 3 trials.
• Genmab’s revenue rose 25% YoY, emphasizing focus on late‑stage pipeline.
• Analysts stay optimistic on Epkinly despite recent bispecific trial miss.

Pulse Analysis

Genmab’s aggressive pruning of its newly acquired ProfoundBio portfolio underscores a disciplined, risk‑averse development philosophy. Within months of the $1.8 billion purchase, the Danish firm terminated GEN1286, an ADC for solid tumors, after the Phase 1/2 trial enrolled just 23 of the planned 260 patients and presented an unfavorable benefit‑risk balance. A parallel shutdown of GEN1057, a DuoBody‑derived bispecific antibody, was justified by marginal anti‑tumor activity. By eliminating underperforming candidates early, Genmab preserves capital for late‑stage programs that promise higher returns.

The sole survivor, Rina‑S, targets folate receptor alpha (FRα), a validated oncology biomarker overexpressed in ovarian, endometrial and non‑small cell lung cancers. Positioned as a potentially best‑in‑class ADC, Rina‑S now advances through Phase 3 trials, directly competing with AbbVie’s $10 billion Immunogen acquisition of the FRα drug Elahere. Success could secure Genmab a foothold in a high‑value therapeutic niche, where FRα‑directed agents are expected to capture multi‑billion‑dollar market share. The company’s focus on this asset reflects confidence in its differentiated linker‑payload technology.

Genmab’s recent culls send a clear signal to investors and partners that pipeline quality trumps sheer volume. The 25 % year‑over‑year revenue growth reported in the latest quarter demonstrates that disciplined investment can coexist with top‑line expansion. Analysts, including Truist Securities, remain bullish on the Epkinly bispecific despite a recent miss, suggesting that the firm’s broader antibody platform retains credibility. For the biotech sector, Genmab’s approach illustrates how strategic M&A—when paired with rigorous internal review—can streamline drug development and protect shareholder value.